Toggle Main Menu Toggle Search

Open Access padlockePrints

Mesenchymal Stromal Cell Therapy for Crohn’s Disease

Lookup NU author(s): Dr Aaron Liew

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Current treatment approaches fail to address the underlying factors responsible for the pathogenesis of Crohn's disease (CD). Mesenchymal stromal cells (MSCs) are fibroblastic plastic adherent cells with specific surface markers, and may demonstrate trilineage differentiation ability. MSCs can be isolated from either the adipose tissue, bone marrow or umbilical cord. In refractory fistulizing CD, both autologous and allogeneic MSC therapy with repeated administrations is a feasible and safe therapeutic option with suggestion of efficacy, and several phase 3 trials are currently underway to determine its efficacy. In this review, we discuss the potential therapeutic role of MSC therapy for CD, which is predominantly related to its immunomodulatory role. The characteristics of MSCs derived from patients with CD and its pharmacological interaction are outlined. Preclinical studies using experimental models of colitis and clinical studies using MSCs for the treatment of fistulizing CD are highlighted. Finally, the current perspective and potential limitations of this novel therapy with recommendations for future studies are discussed.


Publication metadata

Author(s): Liew A, O'Brien T, Egan L

Publication type: Review

Publication status: Published

Journal: Digestive Diseases

Year: 2014

Volume: 32

Issue: Suppl. 1

Pages: 50-60

Print publication date: 01/12/2014

Online publication date: 17/12/2014

ISSN (print): 0257-2753

ISSN (electronic): 1421-9875

URL: http://dx.doi.org/10.1159/000367826

DOI: 10.1159/000367826

PubMed id: 25531353


Share